Australia markets close in 4 hours 26 minutes

OKYO Pharma Limited (EMMLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.07200.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0720
Open0.0720
BidN/A x N/A
AskN/A x N/A
Day's range0.0720 - 0.0720
52-week range0.0585 - 0.1800
Volume5
Avg. volume760
Market cap83.666M
Beta (5Y monthly)0.11
PE ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting

    LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the Annual General Meeting, which was held at 10:00 a.m. today, all resolutions were duly passed. The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news. About OKYO Pharma Limited OKYO P

  • GlobeNewswire

    OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting

    LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it will hold its annual general meeting ("AGM") on Monday 27 September 2021 at 10:00 a.m. The Notice of AGM, together with a proxy form will be posted to shareholders today. The Notice of AGM will shortly also be available on the Compa

  • GlobeNewswire

    OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021

    LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during the last year OK-101 is designed to target a chemokine-like receptor 1, or CMKLR1, which is a G protein-coupled receptor, or GPCR, expressed on macrophages, monocytes, plasmacytoid/myeloid dendritic cells, natural killer cells and nonhemopoietic cell types, such as endothelial and epithelial cells. Acti